First human tests for new lung scarring treatment
NCT ID NCT06746064
Summary
This early-stage study tested the safety and how the body processes an inhaled drug called CHF10073, which is being developed for pulmonary fibrosis (lung scarring). It involved 155 healthy volunteers to check for side effects and measure drug levels in the blood and lungs. The main goal was to see if the drug is safe enough for future testing in people with the actual disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV Clinical Pharmacology Unit
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.